1. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections
- Author
-
Nathaniel C Warner, Amy Carr, Faiqa Cheema, Kathleen Tompkins, Robert Daniels, Luther A. Bartelt, Melissa Jones, Kevin Alby, Anne M. Lachiewicz, Sarah A. Longworth, David E Brown, Michael J Brownstein, Kristin E Linder, Andrew B Gainey, Ryan K. Shields, Anna-Kathryn Burch, David van Duin, Melissa B. Miller, and Jose Alexander
- Subjects
Adult ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Cystic Fibrosis ,medicine.medical_treatment ,030106 microbiology ,Cystic fibrosis ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Lung transplantation ,030212 general & internal medicine ,Child ,Online Only Articles ,biology ,business.industry ,Treatment options ,Achromobacter xylosoxidans ,medicine.disease ,biology.organism_classification ,Anti-Bacterial Agents ,Cephalosporins ,Pneumonia ,Infectious Diseases ,Achromobacter denitrificans ,Gram-Negative Bacterial Infections ,business - Abstract
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
- Published
- 2020
- Full Text
- View/download PDF